{"DataElement":{"publicId":"2665156","version":"1","preferredName":"Chronic Lymphocytic Leukemia Therapy Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility criteria required for therapy for chronic lymphocytic leukemia.","longName":"CLL_TX_CTEC_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2665144","version":"1","preferredName":"Chronic Lymphocytic Leukemia Therapy Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to clinical trial eligibility criteria (elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial) and therapy (an action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process) for chronic lymphocytic leukemia (a slowly progressing disease in which too many white blood cells (called lymphocytes) are found in the body).","longName":"CLL_TX_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2665142","version":"1","preferredName":"CLL Therapy","preferredDefinition":"The most common type of chronic lymphoid leukemia, and comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  The clinical course is indolent, but this type of leukemia is not considered to be curable with available therapy. (WHO, 2001) -- 2003:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C3163:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A1C055-53AA-384C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"ONEDATA","dateModified":"2007-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2494487","version":"1","preferredName":"Clinical Trial Eligibility Criteria","preferredDefinition":"Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"17D7DFE2-3794-35DA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-07-05","modifiedBy":"ONEDATA","dateModified":"2006-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A1C055-53B8-384C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2665155","version":"1","preferredName":"Chronic Lymphocytic Leukemia Therapy Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility criteria required for therapy for chronic lymphocytic leukemia.","longName":"CLL_TX_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"220","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Weight loss of 10% or more within the previous 6 months","valueDescription":"Weight loss of 10% or more within the previous 6 months","ValueMeaning":{"publicId":"2665157","version":"1","preferredName":"Weight loss of 10% or more within the previous 6 months","longName":"2665157","preferredDefinition":"Weight loss of 10% or more within the previous 6 months","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A1D941-36DC-2458-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"35A1960B-4ABE-2332-E044-0003BA3F9857","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"ONEDATA","dateModified":"2007-07-19","deletedIndicator":"No"},{"value":"Extreme fatigue","valueDescription":"Extreme fatigue","ValueMeaning":{"publicId":"2665158","version":"1","preferredName":"Extreme fatigue","longName":"2665158","preferredDefinition":"Extreme fatigue","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A1DAD5-771E-3C74-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"35A1960B-4AD0-2332-E044-0003BA3F9857","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"ONEDATA","dateModified":"2007-07-19","deletedIndicator":"No"},{"value":"Fevers of greater than 100.5 degrees F for 2 weeks without evidence of infection","valueDescription":"Fevers of greater than 100.5 degrees F for 2 weeks without evidence of infection","ValueMeaning":{"publicId":"2665162","version":"1","preferredName":"Fevers of greater than 100.5 degrees F for 2 weeks without evidence of infection","longName":"2665162","preferredDefinition":"Fevers of greater than 100.5 degrees F for 2 weeks without evidence of infection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A25E4F-C81A-1D3D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"35A1960B-4AE2-2332-E044-0003BA3F9857","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"ONEDATA","dateModified":"2007-07-19","deletedIndicator":"No"},{"value":"Drenching night sweats more than 3 times per week without evidence of infection that require the patient to change clothes","valueDescription":"Drenching night sweats more than 3 times per week without evidence of infection that require the patient to change clothes","ValueMeaning":{"publicId":"2665163","version":"1","preferredName":"Drenching night sweats more than 3 times per week without evidence of infection that require the patient to change clothes","longName":"2665163","preferredDefinition":"Drenching night sweats more than 3 times per week without evidence of infection that require the patient to change clothes","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A0FFA3-2F0F-1D3F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"35A1960B-4AF4-2332-E044-0003BA3F9857","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"ONEDATA","dateModified":"2007-07-19","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by hemoglobin <11 g/dL in the absence of autoimmune hemolytic anemia","valueDescription":"Evidence of progressive marrow failure as manifested by hemoglobin <11 g/dL in the absence of autoimmune hemolytic anemia","ValueMeaning":{"publicId":"2665164","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by hemoglobin <11 g/dL in the absence of autoimmune hemolytic anemia","longName":"2665164","preferredDefinition":"Evidence of progressive marrow failure as manifested by hemoglobin <11 g/dL in the absence of autoimmune hemolytic anemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A0FE43-6F58-1910-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2CF77A-9545-5BDB-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by thrombocytopenia <100 x 10^12 /L in the absence of idiopathic thrombocytopenia purpura","valueDescription":"Evidence of progressive marrow failure as manifested by thrombocytopenia <100 x 10^12 /L in the absence of idiopathic thrombocytopenia purpura","ValueMeaning":{"publicId":"2691200","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by thrombocytopenia <100 x 10^12 /L in the absence of idiopathic thrombocytopenia purpura","longName":"2691200","preferredDefinition":"Evidence of progressive marrow failure as manifested by thrombocytopenia <100 x 10^12 /L in the absence of idiopathic thrombocytopenia purpura","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E1521-2280-5C8F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2CF77A-9556-5BDB-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by autoimmune anemia or thrombocytopenia poorly responsive to corticosteroid therapy","valueDescription":"Evidence of progressive marrow failure as manifested by autoimmune anemia or thrombocytopenia poorly responsive to corticosteroid therapy","ValueMeaning":{"publicId":"2691201","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by autoimmune anemia or thrombocytopenia poorly responsive to corticosteroid therapy","longName":"2691201","preferredDefinition":"Evidence of progressive marrow failure as manifested by autoimmune anemia or thrombocytopenia poorly responsive to corticosteroid therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E190A-9114-647B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2CF77A-9568-5BDB-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by massive (i.e., >6 cm below the left costal margin) or progressive splenomegaly that is causing pain or significantly early satiety","valueDescription":"Evidence of progressive marrow failure as manifested by massive (i.e., >6 cm below the left costal margin) or progressive splenomegaly that is causing pain or significantly early satiety","ValueMeaning":{"publicId":"2691202","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by massive (i.e., >6 cm below the left costal margin) or progressive splenomegaly that is causing pain or significantly early satiety","longName":"2691202","preferredDefinition":"Evidence of progressive marrow failure as manifested by massive (i.e., >6 cm below the left costal margin) or progressive splenomegaly that is causing pain or significantly early satiety","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E1A67-5615-6359-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2CF77A-957A-5BDB-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by massive nodes or clusters (i.e., >10 cm in longest diameter) or progressive lymphadenopathy that is causing pain or significant disfigurement","valueDescription":"Evidence of progressive marrow failure as manifested by massive nodes or clusters (i.e., >10 cm in longest diameter) or progressive lymphadenopathy that is causing pain or significant disfigurement","ValueMeaning":{"publicId":"2691203","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by massive nodes or clusters (i.e., >10 cm in longest diameter) or progressive lymphadenopathy that is causing pain or significant disfigurement","longName":"2691203","preferredDefinition":"Evidence of progressive marrow failure as manifested by massive nodes or clusters (i.e., >10 cm in longest diameter) or progressive lymphadenopathy that is causing pain or significant disfigurement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E1521-2290-5C8F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2CF77A-958C-5BDB-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Evidence of progressive marrow failure as manifested by lymphocyte count > 300 x 10^9 /L","valueDescription":"Evidence of progressive marrow failure as manifested by lymphocyte count > 300 x 10^9 /L","ValueMeaning":{"publicId":"2691207","version":"1","preferredName":"Evidence of progressive marrow failure as manifested by lymphocyte count > 300 x 10^9 /L","longName":"2691207","preferredDefinition":"Evidence of progressive marrow failure as manifested by lymphocyte count > 300 x 10^9 /L","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E1D1F-E8AC-5C2D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2E190A-912B-647B-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"},{"value":"Other disease related symptoms (skin infitration, vasculitis, pemphigus)","valueDescription":"Other disease related symptoms (skin infitration, vasculitis, pemphigus)","ValueMeaning":{"publicId":"2691208","version":"1","preferredName":"Other disease related symptoms (skin infitration, vasculitis, pemphigus)","longName":"2691208","preferredDefinition":"Other disease related symptoms (skin infitration, vasculitis, pemphigus)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D2E2586-5272-669C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3D2E1406-400C-638E-E044-0003BA3F9857","beginDate":"2007-10-23","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-23","modifiedBy":"ONEDATA","dateModified":"2007-10-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A2563E-35DD-192E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"A minimum of any one of the f","type":"Preferred Question Text","description":"A minimum of any one of the following disease-related symptoms must be present","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A1D3F2-6D72-3314-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-07-19","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}